P2‐007: Plasma and CSF Aß for the diagnosis of Alzheimer's disease dementia and other dementias in mild cognitive impairment: A Cochrane Systematic Review | Zendy

Ritchie Craig | Zendy; Flicker Leon | Zendy; Smailagic Nadja | Zendy; NoelStorr Anna | Zendy; McShane Rupert | Zendy

Premium

P2‐007: Plasma and CSF Aß for the diagnosis of Alzheimer's disease dementia and other dementias in mild cognitive impairment: A Cochrane Systematic Review

Author(s) -

Ritchie Craig,

Flicker Leon,

Smailagic Nadja,

NoelStorr Anna,

McShane Rupert

Publication year - 2012

Publication title -

alzheimer's and dementia

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 6.713

H-Index - 118

eISSN - 1552-5279

pISSN - 1552-5260

DOI - 10.1016/j.jalz.2012.05.710

Subject(s) - dementia , cognitive impairment , medicine , disease , neuroimaging , receiver operating characteristic , alzheimer's disease , diagnostic accuracy , etiology , meta analysis , psychology , pathology , pediatrics , psychiatry

determined a value (optical density units) for pPKR that could discriminate AD patients from control subjects with a sensitivity of 91.1% and a specificity of 94.3%. Among AD patients, T-PKR and pPKR levels correlate with CSF p181tau levels. Some AD patients with normal CSF As, T-tau, or p181tau levels had abnormal T-PKR and pPKR levels. Conclusions: The evaluation of CSF T-PKR and pPKR levels can discriminate between AD patients and NDC and could help to improve the biochemical diagnosis of AD. Because PKR is pro-apoptotic and pro-inflammatory, this kinase represents a valid pharmacological target to slow the inexorable cognitive decline of AD patients.

This content is not available in your region!

Continue researching here.

Having issues? You can contact us here

Accelerating Research